WoodTrust Financial Corp Acquires New Position in Celcuity, Inc. $CELC

WoodTrust Financial Corp acquired a new stake in shares of Celcuity, Inc. (NASDAQ:CELC) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 5,600 shares of the company’s stock, valued at approximately $277,000.

A number of other large investors have also recently modified their holdings of the business. Rhumbline Advisers increased its stake in shares of Celcuity by 1.2% in the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock valued at $570,000 after purchasing an additional 503 shares during the last quarter. Intech Investment Management LLC boosted its stake in Celcuity by 5.2% in the second quarter. Intech Investment Management LLC now owns 14,855 shares of the company’s stock valued at $198,000 after buying an additional 734 shares in the last quarter. BNP Paribas Financial Markets grew its position in Celcuity by 78.9% in the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after acquiring an additional 1,167 shares during the last quarter. Versant Capital Management Inc grew its holdings in shares of Celcuity by 611.2% during the 3rd quarter. Versant Capital Management Inc now owns 1,593 shares of the company’s stock valued at $79,000 after purchasing an additional 1,369 shares during the last quarter. Finally, Tema Etfs LLC lifted its stake in Celcuity by 8.9% in the 2nd quarter. Tema Etfs LLC now owns 17,011 shares of the company’s stock valued at $227,000 after purchasing an additional 1,392 shares during the last quarter. Institutional investors and hedge funds own 63.33% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on CELC. Needham & Company LLC set a $95.00 price target on shares of Celcuity in a report on Monday, October 20th. Wolfe Research started coverage on Celcuity in a research report on Tuesday, November 18th. They set an “outperform” rating and a $110.00 price objective on the stock. Craig Hallum upped their target price on Celcuity from $96.00 to $108.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. HC Wainwright reissued a “neutral” rating and set a $94.00 price target (up from $77.00) on shares of Celcuity in a research note on Monday, November 17th. Finally, Wells Fargo & Company initiated coverage on Celcuity in a research note on Friday, December 12th. They issued an “overweight” rating and a $126.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $105.25.

Celcuity Stock Up 1.6%

Shares of NASDAQ:CELC opened at $106.96 on Friday. The firm has a market cap of $4.95 billion, a P/E ratio of -29.14 and a beta of 0.25. Celcuity, Inc. has a 12-month low of $7.57 and a 12-month high of $116.44. The business has a fifty day simple moving average of $99.87 and a 200 day simple moving average of $64.98. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 2.74.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.13. Analysts predict that Celcuity, Inc. will post -2.62 earnings per share for the current year.

Insider Activity

In other news, Director Richard E. Buller sold 3,900 shares of the business’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $96.73, for a total value of $377,247.00. Following the transaction, the director owned 7,260 shares in the company, valued at approximately $702,259.80. The trade was a 34.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 15.77% of the company’s stock.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.